MEGGLE introduces new DPI lactose at RDD Online 2021

Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Wasserburg GmbH (MEGGLE) will use the new virtual format Respiratory Drug Delivery (RDD) online conference to unveil InhaLac® 300 as the latest addition to its advanced range of lactose for Dry Powder Inhalation.

MEGGLE has a close and long-standing relationship with the RDD events, extending back more than a decade as both sponsor and regular exhibitor. It will be a prominent presence at the redesigned online event, that will go live over four days from May 4, as well as available on-demand through to June 30.

Bridging the DPI gap

Members of MEGGLE’s R&D team will be available for online chats about the company’s excipients, particularly InhaLac® 300, which has been developed as a fine-milled lactose excipient to support dry powder inhalation (DPI) formulations.

The new excipient’s specific particle size distribution with 90% of particles between 40 and 56 µm and characterized by the typical flow- and surface-characteristic of milled lactose grades allows it to bridge the gap between medium sized carrier lactoses and fine milled grades for DPI.

InhaLac® 300  thus provides an additional tool for formulators to tune and optimize the performance of their DPI products.

About MEGGLE Wasserburg

Bavarian-based MEGGLE is one of the world’s experts in co-processing and powder technology. From its roots as a dairy operation in the late 1880’s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.

MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.

A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI
applications, where they can deliver maximum performance.

The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct
compression co-processed excipient using a hypromellose-lactose base for sustained release formulations.

To learn more, visit: https://www.meggle-pharma.com/en/home.html

About RDD Europe 2021

The Respiratory Drug Delivery (RDD) conference series impacts regulatory and scientific policies worldwide, and are recognized as among the premier international meetings in this area. The RDD Europe conference and co-located exhibition is expected to attract some 500 participants to this international symposium devoted to issues surrounding nasal and pulmonary drug delivery.

The success of the Respiratory Drug Delivery (RDD) Conference series is founded on the selection of internationally renowned speakers, lively audience participation, and the financial support of organizations with a proven commitment to, and record of innovation in the field of inhalation aerosols.

RDD Europe 2021 is a twin element virtual event, with presentations and discussions live streamed online over four days from May 4 between 1600 and 1815 hrs. CEST (UTC +2), and supporting content available on demand between April 27 and June 30.

The event is organized by RDD Online with further information at: https://www.rddonline.com/education/presentations/rdd2021/RDD%20Presentations/Welcome/story.html

Resources

Click on InhaLac brochure to download full product range information.